SanaCurrents on Scholar Rock’s (SRRK) improving treatment for spinal muscular atrophy (SMA)
Scholar Rock Holding Corporatio (NASDAQ:SRRK) Probability Sentiment SUMMARY Spinal muscular atrophy (SMA) is a genetic [...]
SanaCurrents on Wave Life Sciences’ (WVE) precision approach to treating Amyotrophic lateral sclerosis (ALS)
Wave Life Sciences Ltd. (NASDAQ:WVE) Probability Sentiment SUMMARY Approval of Amylyx Pharmaceuticals, Inc.’s (NASDAQ:AMLX) Relyvrio [...]
SanaCurrents on PDUFA decision for SpringWorks (SWTX) first drug to treat desmoid tumors
Springworks Therapeutics, Inc. (NASDAQ:SWTX) Probability Sentiment SUMMARY Desmoid tumors attack the body’s soft tissues, usually [...]
SanaCurrents on the FDA’s lifejacket to Akebia’s (AKBA) anemia drug for dialysis patients
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Probability Sentiment SUMMARY The FDA informed Akebia Therapeutics, Inc. (NASDAQ:AKBA) on [...]
SanaCurrents on Equillium’s (EQ) potential entrant to treat Lupus nephritis (LN)
Equillium, Inc. (NASDAQ:EQ) Probability Sentiment SUMMARY Six-year-old Equillium, Inc.’s (NASDAQ:EQ) lead drug, itolizumab, is in [...]
1 of many SanaCurrents on PDUFA decision for Aldeyra’s (ALDX) new drug to treat dry eye disease
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Probability Sentiment SUMMARY The pipeline at Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) targets [...]
SanaCurrents on Syndax’s (SNDX) rising drug to treat rare, acute leukemias
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Probability Sentiment SUMMARY Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is advancing the small [...]
SanaCurrents on X4 Pharma’s (XFOR) small molecule to treat chronic neutropenia
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Probability Sentiment SUMMARY X4 Pharmaceuticals, Inc.’s (NASDAQ:XFOR) mavorixafor posted impressive clinical [...]